Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NewAmsterdam Pharma Co NV's EBIT per Share for the
three
months ended in Jun. 2026 was $-0.53.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $-2.02.
During the past 3 years, the average EBIT per Share Growth Rate was -116.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -91.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for NewAmsterdam Pharma Co NV's EBIT per Share or its related term are showing as below:
NAMS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -203.1 Med: -116.4 Max: -63.8
Current: -116.4
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of NewAmsterdam Pharma Co NV was -63.80% per year. The lowest was -203.10% per year. And the median was -116.40% per year.
NAMS's 3-Year EBIT Growth Rate is ranked worse than 98.72% of 1171
companies
in the Biotechnology industry
Industry Median: 15.4
vs NAMS: -116.40
NewAmsterdam Pharma Co NV (NAS:NAMS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
NewAmsterdam Pharma Co NV EBIT per Share Related Terms
NewAmsterdam Pharma Co NV EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NewAmsterdam Pharma Co NV (NAMS) has a EBIT per Share of $-2.02 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NewAmsterdam Pharma Co NV and its competitors. According to the industry distribution chart, NewAmsterdam Pharma Co NV ranks #1156 out of 1171 companies in the Biotechnology industry, placing it in the top 98.7%.
Is NewAmsterdam Pharma Co NV's EBIT per Share too high?
NewAmsterdam Pharma Co NV's current EBIT per Share is $-2.02. Based on the distribution chart, NewAmsterdam Pharma Co NV ranks #1156 out of 1171 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's EBIT per Share compare to ARQT and IDYA?
According to the Biotechnology industry distribution chart, NewAmsterdam Pharma Co NV ranks #1156 out of 1171 companies for EBIT per Share. This places NewAmsterdam Pharma Co NV in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NewAmsterdam Pharma Co NV and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewAmsterdam Pharma Co NV's current EBIT per Share is $-2.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.42, compared to a current price of $27.96 — trading 168.3% above its estimated fair value. The current EBIT per Share is $-2.02. NewAmsterdam Pharma Co NV's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current EBIT per Share is $-2.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued.
The current stock price of $27.96 is trading 168.3% above its estimated GF Value™ of $10.42.
GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.
Key valuation signals for NAMS:
EBIT per Share: $-2.02
GF Value™: $10.42 vs. price of $27.96 (168.3% above fair value)
No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
45GF Score
Get the complete analysis for NAMS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAMS has been successfully added to your 
